Journal of Renal Nutrition
Volume 20, Issue 4 , Pages 270-277 , July 2010

Lanthanum Carbonate Is an Effective Hypophosphatemic Agent for Hemodialysis Patients Intolerant of Other Phosphate Binders

  • Wing Lam Winnie Chan, BSc (Hon), PgDip, MSc

      Affiliations

    • Department of Nutrition and Dietetics, Queen Elizabeth Hospital, University Hospital Birmingham NHS Foundation Trust, Edgbaston, Birmingham, United Kingdom
    • Corresponding Author InformationAddress reprint requests to Wing Lam Winnie Chan, BSc (Hon), PgDip, MSc, Department of Nutrition and Dietetics, Nuffield House, 4th Floor, Queen Elizabeth Hospital, University Hospital Birmingham National Health Service Foundation Trust, Edgbaston, Birmingham B15 2TH, United Kingdom.
    • ,
  • Karen Rounsley, BHSc (N&D)

      Affiliations

    • Department of Nutrition and Dietetics, Queen Elizabeth Hospital, University Hospital Birmingham NHS Foundation Trust, Edgbaston, Birmingham, United Kingdom
    • ,
  • Emma Chapman, BSc (Hon)

      Affiliations

    • Department of Nutrition and Dietetics, Queen Elizabeth Hospital, University Hospital Birmingham NHS Foundation Trust, Edgbaston, Birmingham, United Kingdom
    • ,
  • Katherine Collings, BSc (Hon)

      Affiliations

    • Department of Nutrition and Dietetics, Queen Elizabeth Hospital, University Hospital Birmingham NHS Foundation Trust, Edgbaston, Birmingham, United Kingdom
    • ,
  • Clare Dale, BSc (Hon)

      Affiliations

    • Department of Nutrition and Dietetics, Queen Elizabeth Hospital, University Hospital Birmingham NHS Foundation Trust, Edgbaston, Birmingham, United Kingdom
    • ,
  • Susan De Waal, BSc (Hon), PgDip

      Affiliations

    • Department of Nutrition and Dietetics, Queen Elizabeth Hospital, University Hospital Birmingham NHS Foundation Trust, Edgbaston, Birmingham, United Kingdom
    • ,
  • Vandhana Patel, BSc (Hon)

      Affiliations

    • Department of Nutrition and Dietetics, Queen Elizabeth Hospital, University Hospital Birmingham NHS Foundation Trust, Edgbaston, Birmingham, United Kingdom
    • ,
  • Jill Tanner, BSc (Hon), PgDip

      Affiliations

    • Department of Nutrition and Dietetics, Queen Elizabeth Hospital, University Hospital Birmingham NHS Foundation Trust, Edgbaston, Birmingham, United Kingdom
    • ,
  • Elaine Turner, BSc (Hon), PgDip

      Affiliations

    • Department of Nutrition and Dietetics, Queen Elizabeth Hospital, University Hospital Birmingham NHS Foundation Trust, Edgbaston, Birmingham, United Kingdom
    • ,
  • Jason Moore, MB

      Affiliations

    • Department of Nephrology, Queen Elizabeth Hospital, University Hospital Birmingham NHS Foundation Trust, Edgbaston, Birmingham, United Kingdom
    • ,
  • Richard Borrows, MA

      Affiliations

    • Department of Nephrology, Queen Elizabeth Hospital, University Hospital Birmingham NHS Foundation Trust, Edgbaston, Birmingham, United Kingdom

References 

  1. Kalpakian MA, Mehrotra R. Vascular calcification and disordered mineral metabolism in dialysis patients. Semin Dial. 2007;20:139–143
  2. Mehrotra R, Martin KJ, Fishbane S, Sprague SM, Zeig S, Angel M. Higher strength lanthanum carbonate provides serum phosphorus control with a low tablet burden and is preferred by patients and physicians: a multicenter study. Clin J Am Soc Nephrol. 2008;3:1437–1445
  3. National Kidney Foundation . K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(Suppl):S1–S201
  4. Sprogue SM. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate. Curr Med Res Opin. 2007;23:3167–3175
  5. Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000;342:1478–1483
  6. Hercz G, Pei Y, Greenwood C, et al. Aplastic osteodystrophy without aluminium: the role of “suppressed” parathyroid function. Kidney Int. 1993;44:860–866
  7. Raggi P, Bommer J, Chertow GW. Valvular calcification in haemodialysis patients randomized to calcium-based phosphorus binders or sevelamer. J Heart Valve Dis. 2004;13:134–141
  8. Suki WN, Zabaneh R, Cangiano JL, et al. Effects of sevelamer and calcium-based phosphate binders on mortality in haemodialysis patients. Kidney Int. 2007;72:1130–1137
  9. Tomasello S, Dhupar S, Sherman RA. Phosphate binders, K/DOQI guidelines, and compliance: the unfortunate reality. Dial Transplant. 2004;33:236–240
  10. Finn WF, Joy MS, Hladlik G. Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving haemodialysis. Clin Nephrol. 2004;62:193–201
  11. Joy MS, Finn WF. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphataemia. Am J Kidney Dis. 2003;42:96–107
  12. Finn WF. Lanthanum carbonate versus standard therapy for the treatment of hyperphosphataemia: safety and efficiency in chronic maintenance haemodialysis patients. Clin Nephrol. 2006;65:191–202
  13. Hutchison AJ, Maes B, Vanwalleghem J, et al. Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study. Nephron Clin Pract. 2006;102:c61–c71
  14. Clinical Practice Guidelines for Haemodialysis. United Kingdom Renal Association, United Kingdom; 4th ed, 2007.
  15. Salusky IB. A new era in phosphate binder therapy: what are the options?. Kidney Int. 2006;70(Suppl):S10–S15

PII: S1051-2276(09)00287-8

doi: 10.1053/j.jrn.2009.10.009

Journal of Renal Nutrition
Volume 20, Issue 4 , Pages 270-277 , July 2010

Article Tools